

Article

pubs.acs.org/journal/abseba

Platelet Lysate-Loaded Photo-cross-linkable Hyaluronic Acid Hydrogels for Periodontal Endogenous Regenerative Technology

- 3 Pedro S. Babo, †,‡© Ricardo L. Pires,†,‡ Lívia Santos,†,‡ Albina Franco,†,‡ Fernando Rodrigues,‡,§
 4 Isabel Leonor,†,‡ Rui L. Reis,†,‡ and Manuela E. Gomes*,†,‡
- s †3B's Research Group-Biomaterials, Biodegradables and Biomimetics, University of Minho, Avepark-Zona Industrial da Gandra,
- 6 4806-017 Barco GMR, Portugal

9

10

11

12 13

14

15

16

17

18

19

20

21

22

23

24

2.5

2.6


27

28 29

30

- 7 [‡]ICVS/3B's-PT Government Associate Laboratory, University of Minho, Braga/Guimarães 4710-057, Portugal
- 8 Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga 4710-057, Portugal

ABSTRACT: The integrity and function of the periodontium can be compromised by traumatic injuries or periodontitis. Currently available clinical therapies are able to stop the progression of periodontitis and allow the healing of periodontal tissue. However, an optimal strategy capable of restoring the anatomy and functionality of the lost periodontal tissue is still to be achieved. Herein is proposed the development of an injectable hydrogel system able to release a growth factors and cells to the periodontal defect. This injectable system is based on a photo-cross-linkable hydrogel, prepared from methacrylated hyaluronic acid (me-HA) and incorporating platelet lysate (PL). The delivery of growth factors and cells in situ is expected to enhance regeneration of the periodontium. Various formulations of me-HA containing increasing PL concentrations were studied for achieving the formation of stable photo-cross-linkable hydrogels. The produced hydrogels were subsequently characterized to



assess mechanical properties, degradation, protein/growth factor release profile, antimicrobial activity and response toward human Periodontal Ligament fibroblasts (hPDLFs). The results demonstrated that it was possible to obtain stable photo-cross-linkable hydrogels incorporating different amounts of PL that can be released in a sustained manner. Furthermore, the incorporation of PL improved (p < 0.02) the viscoelastic properties of the hydrogels and enhanced their resilience to the degradation by hyaluronidase (HAase). Additionally, the PL was shown to provide antimicrobial properties. Finally, hPDLFs, either seeded or encapsulated into the developed hydrogels, showed enhanced proliferation over time (p < 0.05), proportionally to the increasing amounts of PL present in the hydrogel formulations.

KEYWORDS: photo-cross-linkable hydrogels, platelet lysate, hyaluronic acid, periodontal ligament, endogenous regenerative technology

31 ■ INTRODUCTION

32 The periodontium is a complex and dynamic oral structure 33 comprising soft and hard tissues, the cementum, a functionally 34 oriented periodontal ligament, alveolar bone and gingiva The 35 main function of this structure is anchoring the teeth to the jaw 36 bones, while withstanding the forces originated by the 37 masticatory process. The integrity and function of the 38 periodontium can be compromised by trauma or disease, 39 such as periodontitis, an inflammatory disease predominantly 40 caused by Gram-negative bacteria that causes the destruction of 41 these tooth supportive tissues potentially leading to tooth 42 loss. ^{1,2}

Current therapeutic options, which include the implantation of autografts, synthetic bone fillers and guided tissue regeneration (GTR), are not able to fully regenerate periodontium morphology and function. In recent years endogenous regenerative technology (ERT) has arisen as a new paradigm in periodontal regeneration. This new concept has its foundations in tissue engineering and aims to induce or

encourage periodontal regeneration by superimposing specific 50 chemical (e.g., growth factors) and biophysical cues.³ These 51 signals are expected to encourage homing of stem and 52 progenitor cells, leading to the formation of new periodontal 53 ligament and cementum.³

Platelet-rich hemoderivatives (PRHds), namely platelet-rich 55 plasma and platelet-rich fibrin, have been widely investigated 56 for periodontal ERT as important sources of autologous growth 57 factors and provisional fibrin matrices. 1,3 Nevertheless, the 58 traditional PRHds clots retract, impairing the needed stability 59 for periodontal tissue ingrowth. In this research work we 60 propose the development of photo-cross-linkable hyaluronic 61 acid hydrogels enriched with platelet lysate as a stable system 62

Special Issue: Biomimetic Bioactive Biomaterials: The Next Generation of Implantable Devices

Received: August 31, 2016 Accepted: December 20, 2016 Published: December 20, 2016



ACS Biomaterials Science & Engineering




Figure 1. (A) Scheme of the methacrylation process of Hyaluronic acid using methacrylic anhydride. (B) Representative image depicting a typical me-HA/PL hydrogel obtained by photopolimerization. (C) FTIR Spectra of HA and me-HA produced with 5 and 10× molar excess of (5× and 10× me-HA). (D) 1 HNMR spectra of HA, 5× me-HA and 10× me-HA: (a) vinyl groups of MA (δ 5.77–6.20 ppm); (b) methyl group of the N-acetyLD-glucosamine (δ 2.05 ppm); and (c) methyl group of MA (δ 1.94 ppm).

63 for the delivery of endogenous GFs, directed for periodontal 64 ERT.

It is advocated that current ERT scaffolding materials needs 66 sophistication and that should be employed in a patient-tailored 67 fashion using preferably own patients' biological material.³ In 68 this sense, platelet lysate (PL) offer great potential in 69 regenerative medicine as an alternative source of growth factors (GFs). 5,6 These PL-origin GFs, include fibroblast growth factor 71 (FGF), vascular endothelial growth factor, platelet-derived 72 growth factor, transforming growth factors- $\beta 1$ and - $\beta 2$, insulin-73 like growth factor, epidermal growth factor, epithelial cell 74 growth factor, hepatocyte growth factor, and bone morphoge-75 netic proteins 7-9 are known to be involved in essential stages of 76 wound healing and regenerative processes such as chemotaxis, 77 cell proliferation and differentiation. 10,11 Moreover, platelets release numerous cell adhesion molecules (fibrin, fibronectin, and vitronectin) which can provide a provisional matrix for the 80 adhesion and migration of cells. 10 In addition, platelet concentrates (PCs) have also been reported to exhibit 82 antimicrobial properties¹² and the PL, as a product of PCs 83 activation, is expected to have the same antimicrobial 84 properties, contributing for the prophylaxis of the wound site. 85 In fact, the use of PL holds several advantages over other 86 PRHds, which include the ease of standardizing the production 87 process and the higher consistency in GF content between

batches,⁵ that is expected to yield more predictable clinical 88 outcomes.

Because PL is obtained as a liquid solution, it was 90 incorporated in a photo-cross-linkable HA matrix. HA is a 91 glycosaminoglycan copolymer of D-glucuronic acid and N- 92 acetyl-D-glucosamine that is present in connective tissues and 93 plays an important role in several cellular processes including, 94 cell proliferation, morphogenesis, inflammation, and wound 95 repair. HA-based biomaterials have demonstrated positive 96 results for several potential applications in the regeneration of 97 hard or soft tissues. Moreover, given HA anti-inflammatory, 98 antiedematous, and antibacterial effects, it has been also 99 proposed for the treatment of lesions caused by periodontal 100 diseases. 15–17

The aim is to characterize these PL-rich scaffolds with regard 102 to mechanical properties, release of proteins, periodontal cell 103 response, and antimicrobial action against dental plaque 104 bacteria. This new ERT scaffold offers a new and promising 105 periodontal treatment modality that should encourage tissue 106 regeneration through the release of PL-derived GFs while 107 providing concomitant antimicrobial action. Furthermore, 108 functionalization of HA with methacrylic groups allows the 109 production in situ of stable photopolymerizable hydrogels, 110 enabling the application in periodontal defects in a clinical 111 scenario.

113 MATERIALS AND METHODS

Materials. HA obtained from Streptococcus equi ($M_{\rm w}=1.5$ to 1.8 MDa), methacrylic anhydride Irgacure 2959 (2-hydroxy-4-(2-hydrox-116 yethoxy)-2-methylpropiophenone), hyaluronidase type IV from bovine 117 origin (HAase), phosphate buffered saline (PBS), phalloidin-118 tetramethylrhodamine B isothiocyanate 4,6-diamidino-2-phenylindole, 119 dilactate (DAPI) and the dialysis tubing cellulose membrane were all 120 purchased from Sigma (Sigma-Aldrich, USA). Sodium hydroxide 121 (NaOH) and hydrochloride acid (HCl) were purchased from VWR 122 Chemicals (BDH, Prolabo - international, USA). Alpha MEM (α -123 MEM) culture medium and fetal bovine serum (FBS) were purchased 124 from Gibco (Life Technologies, UK). Deuterium oxide (2 H₂O) was 125 purchased from LaborSpirit Ida (PT) and the polydimethylsiloxane 126 (PDMS) from Down Corning (USA). The Muller—Hinton agar plate 127 was obtained from Oxoid (UK).

Preparation of Platelet Lysate (PL). PL was obtained from different lots of platelet concentrates provided by Serviço de 130 Imunohematologia do Centro Hospitalar de São João (CHSJ, Porto, 131 Portugal), based on a previously established protocol. To produce PL, 132 batches of platelet concentrates obtained by plasma apheresis with a 133 density of 10^6 cells/ μ L and biologically qualified according to 134 Portuguese legislation (Decreto-Lei No. 100/2011) were processed 135 as previously described. ^{18,19} Very briefly, platelet concentrates from 136 three different donors were pooled and exposed to three repeated 137 freezing and thaw cycles (frozen with liquid nitrogen and thawed in a 138 37 °C water bath) to promote the lysis of the platelets and release of 139 GFs. Afterward, the lysis product was centrifuged at 1400 rcf for 10 140 min and the supernatant stored at -20 °C until further use. ^{18,19}

Methacrylation of Hyaluronic Acid (HA). The method followed for the methacrylation of HA was based on a previously described protocol, 20 (depicted in Figure 1A), consisting in the addition between 144 5- to 10-fold molar excess (5× and 10×) of methacrylic anhydride 145 (MA) to a solution of 1 wt % HA in distilled water (dH₂O). The pH was adjusted between 8 and 8.5 with 5N NaOH added dropwise. The reaction occurred during 24 h at 4 °C provided by an ice bath. Subsequently, the reaction products were precipitated using cold ethanol (at -20 °C). Then the precipitate was dissolved in dH₂O and dialyzed using a membrane with a cutoff of 14 000 kDa for a week against mili-Q water, replaced 3 times a day, to remove the unreacted reagents and byproducts. Finally, the solution was filtered, frozen at -80 °C and the methacrylated HA (me-HA) recovered upon 154 lyophilization.

Characterization of the me-HA. Fourier transform infrared spectroscopy (IR-Prestige-21, FTIR Shimadzu) was used to record the infrared spectra of HA and me-HA. Briefly, a small portion of each batch was mixed with potassium bromide, and processed into pellets. The spectra were obtained in the range of 400 to 4000 cm⁻¹ at a 4 160 cm⁻¹ resolution with 32 scans. HNMR spectra were recorded with a 161 Varian Inova 500 at 70 °C. me-HA solutions were prepared for analysis by dissolving 5 mg of me-HA in 1 mL of ²H₂O. The degree of methacrylation (Dmet) was defined as the percentage of methacryloyl groups per HA disaccharide repeat unit and was calculated from the 165 ratio of the relative peak integration of the methacrylate protons 166 (peaks at ~6.20, ~ 5.77, and ~2.05 ppm) and HA's methyl protons 167 (~1.98 ppm).

Development of the Photo-cross-linkable me-HA Hydrogels Incorporating PL. The development of the photo-cross-linkable me-170 HA hydrogels incorporating PL was optimized by changing the HA 171 (5x and 10x MA molar excess) solution concentration (1 and 2 wt %), 172 the concentration of photoinitiator Irgacure 2959 (0.1 and 0.2 wt/v%), 173 the power of the UV light, the distance to the UV light source, and the 174 concentration of PL incorporated in the solvent solution (Table 1). PL 175 was incorporated in the solvent solution in increasing volumetric 176 concentrations ranging from pure water (0% PL) to pure PL (100% 177 PL). To obtain hydrogels, dry me-HA was dissolved in the solvent 178 solution containing the photoinitiator. Then, 25 μ L of me-HA solution 179 were injected into a circular (5 mm diameter) PDMS mold and 180 exposed to a UV light (Omnicure series 2000 EXFO S2000-XLA, 181 Omnicure, Canada) to trigger the photo-cross-linking, producing disk-

Table 1. Summary of the Formulations Studied for the Optimization of the Hyaluronic Acid Hydrogels Incorporating PL (HAPL)^a

me-HA (wt/v%)	Irgacure (wt/v%)	PL (v/v%)
1	0.10	0
		50
		100
	0.20	0
		50
		100
2	0.10	0
		50
		100
	0.20	0
		50
		100

"The concentrations of me-HA and Irgacure 2959 are presented as weight/volume percentage. The PL concentrations are volumetric concentrations of pure PL (100%PL) in water (0%PL). All the formulations were prepared using both the batches of me-HA ($5\times$ and $10\times$ molar excess).

shaped hydrogels. The produced formulations, incorporating 0, 50 and 182 100% PL, were designated PL $_0$, PL $_{50}$, and PL $_{100}$, respectively. 183

Characterization of the HAPL Hydrogels. Only the 10× me- 184 HA batch allowed obtaining the hydrogels by photopolymerization, 185 using either 0.1 or 0.2% of photoinitiator, so this batch was selected for 186 all further studies. Considering that Igacure 2959 presents some 187 cytotoxicity, 21 it was also decided to use the lower photoinitiator 188 concentration for the following characterization steps.

Evaluation of the Mechanical Properties by DMA. The 190 viscoelastic properties of the developed hydrogels (PL₀, PL₅₀, and 191 PL₁₀₀ with 1% or 2% of me-HA and with 0.1% of Irgacure) were 192 evaluated by dynamic mechanical analysis (DMA) (TRITEC8000B, 193 Triton Technology, UK), equipped with the compressive mode. DMA 194 spectra were obtained during a frequency scan ranging between 0.1 195 and 15 Hz for all time points. The experiments were performed under 196 constant strain amplitude, corresponding to approximately 1% of the 197 original height of the sample. Samples were tested while immersed in 198 PBS and at 37 °C, to simulate the physiological conditions.

Swelling and Weight Loss. The results obtained from the DMA 200 analysis revealed better mechanical properties for the 2% me-HA 201 formulation and thus this was selected for the subsequent studies, 202 namely degradation, protein release and cell response. Thus, 203 formulations of hydrogels with increasing concentrations of PL (PL $_0$, 204 PL $_0$), were prepared into disc-shaped samples of 5 mm in 205 diameter and 1 mm thickness, as above-described, and placed in 24 206 wells plate.

Periodontal ligament fibroblasts express hyaluronidase (HAase) and 208 generate HAase activity that regulates extracellular hyaluronan 209 metabolism. ²² Given the presence of this enzyme in the periodontium, 210 the degradation promoted by a HAase was investigated. Similar assay 211 was conducted in PBS. Each sample was incubated in 1.6 mL of PBS at 212 37 °C, pH 7.4. For the enzymatic degradation assays, the same 213 formulations were incubated at 37 °C in 1.6 mL of a HAase solution of 214 100 U/mL in PBS.

The assays were carried out using 4 samples of each formulation 216 immersed in each of the solutions. The samples were retrieved after 1, 217 3, 7, 14, and 21 days of incubation.

The wet weight of the samples was registered (PI-214 analytical 219 balance, Denver Instrument Company, USA) at each predetermined 220 time point. The dry weight of the samples was also registered after 221 allowing samples to dry overnight at 37 $^{\circ}$ C. The percentage of weight 222 loss was calculated according to eq 1 223

weight loss =
$$\frac{(m_i - m_f)}{m_i} 100$$
 (1) 224

327

225 where m_i is the initial weight and m_f the final weight.

229

The water uptake ratio was also calculated following eq 2 by dividing each sample wet mass $(m_{\rm wet})$ by the final dry hydrogel mass 228 $(m_{\rm dry})$.

water uptake ratio =
$$\frac{m_{\text{wet}}}{m_{\text{dry}}} 100$$
 (2)

Quantification of Protein Release. Protein release from PL_{07} and PL_{100} was quantified after 30 min, 1, 4, and 8 h, and 1, 7, 14, 232 and 21 days of incubation in PBS at 37 °C. For this purpose, at each ime point, a volume of supernatant was collected and stored at -20 234 °C. The total protein content was quantified using a micro BCA 235 protein assay (Thermo Fischer Scientific, USA), following the 236 manufacturer's instructions. Additionally, the release of fibroblast 237 growth factor-2 (FGF-2), present in the PL, was also quantified using 238 an enzyme-linked immunosorbent assay kit (Human FGF-basic, 239 ELISA Development Kit, by PeproTech, USA), according to 240 manufacturer's instructions.

Evaluation of the Response of Human Periodontal Ligament Fibroblasts (hPDLFs). The response of hPDLFs to the 243 photo-cross-linked me-HA/PL hydrogels was assessed upon either encapsulation or seeding of the cells onto the hydrogels surface and 245 further cultured for up to 14 days.

The hPDLFs (ScienCell Research Laboratories) at passage 3 were seeded on disc-shaped (5 mm diameter) samples of the formulations PL $_{00}$ PL $_{50}$, and PL $_{100}$ produced as previously described, at a cell density of 5 \times 10⁴ cm $^{-2}$. A 50 μ L drop of a cellular suspension containing 1 \times 10⁴ cells was seeded on the surface of each sample, previously placed in a 24 wells plate, and allowed to adhere for 1 h. After this period, 450 μ L of α -MEM basal medium (supplemented with 10% of FBS and 1% antibiotic-antimycotic) were added to each well. The 24 wells plates containing the cell-seeded hydrogels were further incubated at 37 °C, 255 5% CO $_2$ for 1, 4, 7, and 14 days, renewing the culture medium every 3 days. Cells cultured on polystyrene coverslips (Sarstedt) were employed as positive control.

For the encapsulation, hPDLFs cells were resuspended in 2% me-259 HA solutions containing 0, 50 and 100% PL to obtain a final cell 260 density of 4×10^6 cells mL⁻¹. Then, 25 μ L (1×10^5 cells) of the 261 cellular suspension in each hydrogel solution formulation was injected 262 into circular molds (5 mm diameter) and exposed to UV light, as 263 previously described to obtain the hydrogel samples. The cell-laden 264 hydrogels were subsequently transferred to individual wells of 24-well 265 plates, each one containing 500 μ L of basal medium. The 24-wells 266 plates were incubated at 37 °C, 5% CO₂ for 1, 4, 7, and 14 days 267 renewing the culture medium every 3 days.

The metabolic activity of the cells seeded/encapsulated in the hydrogels and further cultured was evaluated using the Alamar blue assay (AbDseroTec, USA), following the manufacturer's instructions. Briefly, at each time point, the culture medium was discarded, the samples were washed twice with PBS and then incubated in a 10% Alamar blue solution in basal medium (450 μ L of basal medium, and 50 μ L of Alamar blue) at 37 °C, 5% CO₂ for 150 min. The microplate reader (Synergy HT, Biotek, USA) at 560 nm of excitation and 590 nm of emission.

The cellular proliferation was also evaluated as a function of the 279 dsDNA quantification using the PicoGreen dsDNA quantification kit, 280 according to manufacturer's specifications (Life Technologies, USA).

Finally, the morphology and the migration of the cells either 282 encapsulated or seeded on the surface of the hydrogels were 283 investigated by confocal microscopy, upon staining with DAPI and 284 phalloidin. For this purpose, samples retrieved after each of the preset 285 culturing times were fixed with 10% formalin (in PBS) for 30 min at 286 room temperature. Afterward, the samples were washed 2 times with 287 PBS to remove the formalin and 300 μ L of phalloidin solution (1:100 288 in PBS) were added per well and incubated 1 h at room temperature. 289 Then phalloidin solution was discarded and the samples were washed 290 3 times with PBS. A DAPI solution (1:1000 in PBS) was prepared and 291 300 μ L were added per well and incubated 5 min. The samples were 292 washed 3 times and the prepared for visualization under a confocal

microscopy (TCS SP8 from Leica Mycrosystems CMS GmbH) with 293 Vectashield mounting medium.

Antimicrobial Assay. The antimicrobial activity of PL soluble 295 factors released form from the HA hydrogels was evaluated using the 296 radial diffusion assay, according to Kirby-Bauer method.²³ Five 297 different bacteria species were used: the Gram-positive bacteria 298 Bacillus megaterium (Internal collection), Methicillin Resistant Staph- 299 ylococcus aureus (MRSA) (Internal collection), and Vancomycin 300 Resistant Staphylococcus aureus (VRSA) (internal collection) and the 301 Gram-negative species Pseudomonas aeruginosa T6BT12, Escherichia 302 coli DH5 α) and the fungus Candida albicans (Internal collection). 303 With the exception of P. aeruginosa, which was isolated from 304 environmental samples, all the other microorganisms were isolated 305 from clinical samples. Prior to the antimicrobial activity testing, these 306 microorganisms were cultured aerobically in Luria-Bertani broth at 37 307 °C overnight with agitation (150 rpm). Afterward, they were 308 centrifuged at 8000 rpm for 5 min, and washed three times with 309 PBS. Microbial cultures were adjusted to a concentration correspond- 310 ing to ca. 1×10^7 CFU mL⁻¹, and pipetted with 0.4% agar into a Petri 311 dish containing 5 mL of Muller-Hinton (MH) Agar plate.

The PL_0 , PL_{50} and PL_{100} hydrogels and the negative control (PBS) 313 were placed on MH–agar plates and cultured with each of microbial 314 strain at 37 °C for 16 h, upon which the inhibition halo measure and 315 the general macroscopic response was recorded. Experiments were 316 performed in triplicate.

Statistical Analysis. All the experiments were performed with at 318 least three replicates. All the cell culture experiments were performed 319 simultaneously in order to reduce the variability intra-assay and 3 320 independent studies were performed, exactly as described. Results are 321 expressed as mean \pm standard error of the mean (SEM). Statistical 322 analysis was performed by repeated measures Two-way ANOVA 323 comparison test (* p < 0.05, ** p < 0.01 and *** p < 0.001 for 324 statistically significant differences) using the software Graph Pad Prism 325

RESULTS

Development of the Photo-cross-linkable me-HA $_{328}$ Hydrogels. HA methacrylation. In this study, unmodified $_{329}$ hyaluronan was methacrylated Reacting a 1% HA aqueous $_{330}$ solution at pH 8, with $_{5\times}$ and $_{10\times}$ of molar excess of MA for $_{331}$ 24h at 4 °C.

The methacrylation of HA was confirmed by the FTIR 333 spectra, where the deep peak at 1715 cm $^{-1}$ represents the 334 carbonyl ester group resultant from the methacrylation (Figure 335 1C). Moreover, the 1 HNMR spectra of the me-HA batches 336 (Figure 1D) exhibited the presence the characteristic peaks 337 corresponding to the two protons of the double bond region (δ 338 5.77 and 6.20 ppm) of the MA group absent in the 339 nonmodified HA spectrum.

The degree of methacrylation was calculated from the ratio 341 of the relative peak integration of the methacrylate protons 342 (peaks at \sim 6.20, \sim 5.77, and \sim 2.05 ppm) and the methyl 343 protons of N-acetyl-D-glucosamine (\sim 1.98 ppm). A Dmet of 344 14% was obtained for the me-HA batch produced with $^{5\times}$ 345 excess of MA ($^{5\times}$ me-HA), while the batch produced with $^{10\times}$ 346 excess MA ($^{10\times}$ me-HA) presented a Dmet of 24%.

Mechanical Properties of the Developed Hydrogels. 348 Dynamic mechanical analysis (DMA) experiments were 349 performed in a hydrated environment at 37 °C, in an array 350 of biologically relevant frequencies, in order to assess the 351 viscoelastic properties of the samples in a physiological-like 352 environment. Both storage (elastic) modulus, E', and the loss 353 factor, $\tan \delta$, were obtained at different frequencies. E' is a 354 measure of the materials stiffness. The loss factor is the ratio of 355 the amount of energy dissipated (viscous component) relative 356 to energy stored (elastic component); $\tan \delta = E'/E''$.




Figure 2. Variation in (A) elastic modulus (E') and (B) loss factor (tan δ) with frequency of 1% and 2% HA hydrogels incorporating 0, 50, and 100% v/v PL (PL₀, PL₅₀, and PL₁₀₀) measured by dynamic mechanical analysis. Differences observed on (C) elastic modulus (E') and (D) loss factor (tan δ) at 1 Hz. * p < 0.05, *** p < 0.02; **** p < 0.001.




Figure 3. Weight loss (A, B) and (C, D) swelling ratio profile of $PL_{0,}$ PL_{50} , and PL_{100} hydrogels in (A, C) PBS and (B, D) HAase solution (100 U/mL). (a) Statistically different (p < 0.05) from PL_{100} ; (b) statistically different (p < 0.05) from PL_{50} ; (c) statistically different (p < 0.05) from PL_{50} and PL_{50} .

f2

371

362 hydrogels also increased above three to four times, from 363 approximately 100 kPa to 428-600 kPa, in formulations 364 incorporating PL (PL₅₀ and PL₁₀₀). The concentration of PL in 365 the hydrogels also showed to influence the elastic modulus that was found to increase proportionally with the amount of PL. The formulation that exhibited the highest elastic modulus corresponds to the formulation containing 2% of me-HA dissolved in 100% PL. 369

Degradation Behavior. The weight loss and swelling ratio profiles of the PL₀, PL₅₀ and PL₁₀₀ hydrogels after incubation in PBS or HAase (100U/mL) solution at 37 °C for 1, 3, 7, and 14 days are presented in Figure 3.

Weight Loss. Overall, the results obtained showed that the 375 incorporation of PL in me-HA hydrogels influences its stability. Although the PL₀ hydrogels showed lower weight loss until the seventh day of immersion in PBS, they were completely degraded after 14 days (Figure 3A). On the other hand, despite the weight loss profile of the formulations incorporating PL is characterized by an initial loss of around 70% of the dry weight in the first 3 days, the PL₅₀ and PL₁₀₀ hydrogels tend to be 381 382 more stable along immersion time in PBS.

The weight loss results obtained upon immersion in HAase, 383 384 revealed that PL₁₀₀ formulation displays higher degradability, 385 upon the first day. Nevertheless, it was found that samples containing PL were only completely degraded after 14 days, while all the hydrogels of the PL₀ formulation were completely degraded after only 3 day of immersion in the enzymatic solution.


Swelling Ratio. In the beginning of the assay, the swelling of 390 391 freshly produced PL₁₀₀ hydrogels was significantly lower than the formulations with lower PL concentration. When immersed in the PBS solution the PL₀ and PL₅₀ hydrogels, did not show significant statistical differences among them for all the time points studied. Accordingly, both hydrogels formulations presented a similar profile characterized by a peak around day (1500% for PL_{50}) and day 3 (1000% for PL_0), followed by a decrease of swelling until the end of the assay, because of the total degradation of the material. On the other hand, PL₁₀₀ 400 hydrogels had a later peak at day 7, reaching near 1400% of swelling. 401

Regarding the swelling in HAase solution, the values were 402 403 statistically similar for PL₀, PL₅₀ and PL₁₀₀ hydrogels. 404 Nevertheless, while the formulations PL₀ and PL₅₀ depicted a similar behavior, presenting a constant decrease in the swelling values from the beginning of the assay, the PL₁₀₀ formulation reached an average swelling of 1400% at day 7, before starting to decrease.

Protein Release. The total amount of protein released from 410 me-HA/PL hydrogels over time is represented in Figure 4.

Both PL₅₀ and PL₁₀₀ hydrogels displayed a similar release profile that is characterized by an initial "burst" of protein released during the first hour, that represents around 15% for PL₁₀₀ hydrogels and 25% for PL₅₀ hydrogels of the total protein contained, followed by a sustained release up to 14 days. 416 Although no statistically significant differences were observed between the formulations during the first day of release, there was a substantial difference in the amount of protein released 419 by the PL₁₀₀ formulation, which is proportional with the 420 amount of protein incorporated in the formulations.

To evaluate the release of PL-specific GFs from the 422 developed HA hydrogels, and the interaction of the GFs with 423 the HA mesh, hydrogels were incubated either in PBS or in 100






Figure 4. Total protein released from the hydrogels containing PL, (A) assessed using the Pierce BCA protein assay kit incubated in PBS. Fibroblasts growth factor (FGF) release, (B) assessed using the PeproTech ELISA development kit incubated in HAase solution (100 U/mL). ** p < 0.02; *** p < 0.001.

U/mL HAase solution and the release products were quantified 424

The results for the release of FGF-2, depicted in Figure 4B, 426 showed that the PL₅₀ and PL₁₀₀ had a different profile for FGF- 427 2 release. The FGF-2 released by PL₅₀ was characterized by an 428 initial burst of release up to day 3, as observed. After day 3, the 429 release kinetics reached an apparent plateau, and a slow 430 sustained delivery remained up to day 21. On the other hand, 431 PL₁₀₀ hydrogels showed a sustained release, progressing in a 432 linear way, during all the duration of the assay, without signs of 433 deceleration. Nevertheless, despite the PL₁₀₀ hydrogels have 434 higher amount of total protein incorporated, they depicted a 435 FGF-2 release similar to the PL₅₀ hydrogel.

Cell Response to the Developed Hydrogels. The response 437 of hPDLFs, either surface seeded or encapsulated onto the PL₀, 438 PL_{50} and PL_{100} hydrogels was assessed. In both the cases, the 439 increasing amounts of PL in the hydrogels had a positive effect 440 in the cells metabolic activity and proliferation rate as shown in 441 Figure 5.

The results presented in Figure 5A show that there were no 443 significant differences between the PL₀ and PL₅₀ hydrogels with 444 respect to proliferation and metabolic activity of encapsulated 445 cells. Remarkably, PL₁₀₀ hydrogels exhibited higher cell growth 446 and metabolic activity than PL₀ and PL₅₀ hydrogels. Regarding 447 the morphology of the encapsulated cells, Figure 5B shows that 448 hPDLFs dispersed and stretched inside of the hydrogels, 449 following the alignments of the fibrous structures observed 450 macroscopically in the hydrogels.

The Figure 5C shows the behavior of the hPDLFs cells when 452 seeded at the surface of the PL_0 , PL_{50} and PL_{100} hydrogels. No 453




Figure 5. Response of hPDLFs seeded/encapsulated on the hydrogels with the formulations PL_0 , PL_{50} , PL_{100} . (A) DNA quantification and metabolic activity of encapsulated cells. (B) DNA quantification and metabolic activity of seeded cell. (C) Representative pictures of hPDLFs encapsulated in PL_{50} and PL_{100} hydrogels, stained with DAPI (blue) and phalloidin (red). for 21 days. The small micrographs on the bottom left depict the spindlelike shape morphology of the hPDLFs encapsulated into the hydrogels. (D) hPDLFs seeded on PL_{50} and PL_{100} hydrogels and cultured for 21 days, stained with DAPI (blue) and Phalloidin (red).




Figure 6. Three-dimensional reconstruction obtained by confocal microscopy of hPDLFs distribution on PL₁₀₀ hydrogels at day 21.

454 significant differences were seen in terms of seeding efficiency 455 on the hydrogels and on the PS positive control.

The analysis of hPDLFs distribution throughout the PLrepriched hydrogels, obtained by confocal microscopy from PL_{100} hydrogels 21 days after being seeded on the surface, is represented in Figure 6. This picture shows that hPDLFs is seeded in the surface of the hydrogels migrated up to 70 μ m is deep into to the hydrogel after 21 days in culture.

Antimicrobial Activity. The antimicrobial effect of PL 463 soluble factors against Pseudomonas aeruginosa, Candida 464 albicans, Escherichia coli, Bacillus megaterium, Staphylococcus 465 (VRSA), and Staphylococcus (MRSA) was evaluated.

The antimicrobial properties of the developed hydrogels containing PL were assessed using the agar well diffusion the method, adapted from the Kirby-Bauer original method for testing microbial resistance to antibiotic drugs. The Figure 7 kpc shows the effect of the hydrogels incorporating increasing amounts of PL in the Pseudomonas aeruginosa, Candida albicans,

and Escherichia coli and, Bacillus megaterium, vancomycin- 472 resistant Staphylococcus aureus (VRSA), and methicillin- 473 resistant Staphylococcus aureus (MRSA).

The release of PL provides antimicrobial action against 475 methicillin resistant Staphylococcus aureus, as shown by the 476 inhibition of growth in the space occupied by the PL_{100} 477 hydrogel (Figure 7F). Moreover, it is dependent on the PL 478 content, because no inhibition hallo was observed for the 479 formulations with lower amounts of PL incorporated (PL_0 and 480 PL_{50}). Nevertheless, despite no inhibition halo was observed in 481 the rest of the species for the formulations investigated, no 482 degradation or bacterial growth on the hydrogel surface was 483 reported.

DISCUSSION

The present work describes the development of novel photo- 486 cross-linkable hydrogels incorporating allogenic platelet lysate, 487 a platelet rich hemoderivative (PRHd), aimed at endogenous 488

485

ACS Biomaterials Science & Engineering




Figure 7. Antimicrobial assay for (i) PL₁₀₀, (ii) PL₅₀, and (iii) PL₀ formulations where control is (iv) PBS using (A) *Pseudomonas aeruginosa*, (B) *Candida albicans*, (C) *Escherichia coli* (E. coli), (D) *Bacillus megaterium*, (E) vancomycin-resistant *Staphylococcus aureus* (VRSA), and (F) methicillin-resistant *Staphylococcus aureus* (MRSA).

489 regenerative technology (ERT) being used for the regeneration 490 of periodontal ligament. PL can be used in clinical applications as an autologous therapy. However, several authors 5,24 have 492 reported high donor-to-donor variability in PRHds batches, which could correlate with the high variability associated with 494 the clinical outcomes of PRHds treatments. 25 On the other 495 hand, Crespo-Diaz et al.⁵ reported lower variability in PL 496 batches produced from outdated platelet concentrates obtained 497 by plasma apheresis from different donors; therefore more predictable therapeutic outcomes could be anticipated. 499 Furthermore, these PL batches were shown to be safe of 500 standard pathogens and infectious diseases. In the present 501 work, were used outdated (>5 days old) platelet concentrates obtained by plasma apheresis and biologically qualified according to Portuguese legislation (Decreto-Lei No. 100/ 2011) for blood products collection, transport and therapeutic administration. Therefore, these PL batches are expected to be 506 as safe as any other blood component aimed for therapeutic administration and used in allogenic PL-based strategy as proposed. The combination of me-HA with PL, as herein 509 proposed, produced a photo-cross-linkable system with several 510 advantages for tissue engineering applications. Being injectable, these biomaterials can be implanted using minimally invasive techniques without requiring surgical interventions. Moreover, the system can fit perfectly to irregular-shaped defects, deeply interacting with the preserved tissue margins, before being photo-cross-linked to produce a stable matrix.

With regard to viscoelastic properties, DMA analysis revealed that these hydrogels exhibit elastic modulus ranging from 264 \pm 81 kPa for the PL₀ formulation to 600 \pm 186 kPa to the PL₁₀₀ formulation (at 1 Hz), comparable to other HA hydrogels incorporating fibrin described for artificial cartilage implantation (445 kPa), ²⁶ which support the use of our photo-cross-linkable hydrogels for soft tissue reconstruction. Moreover, periodontal tissue is continuously subjected to very dynamic

forces, acting the periodontal ligament as a damper.^{27,28} 524 Therefore, the viscoelastic properties displayed by the hydro- 525 gels herein developed are of paramount importance for 526 periodontal therapy approaches. 527

Regarding the degradation of HA hydrogels, it was faster in 528 the presence of the HAase, the specific enzymes that degrade 529 the HA in vivo,²⁹ than in saline solution, as previously 530 reported. 13,30 Remarkably, the PL-enriched hydrogels remained 531 stable for longer periods. The time to total degradation of PL_{100} 532 was even longer when compared with other HA hydrogels 533 exposed to similar conditions. 13 It should be noted that in this 534 study we used a supra-physiologic concentration of HAase (100 535 U/mL), which in human plasma ranges from 0.0028 \pm 0.0004 536 U/L to 3.8 ± 0.7 U/L depending on patient health condition.³¹ 537 Therefore, these findings suggest that PL-enriched photo-cross- 538 linkable HA hydrogels, may maintain the necessary space 539 stability in vivo for new tissue ingrowth.⁴ Such reinforcement is 540 attributed to the presence of fibrinogen in the PL, 1,18 as this 541 protein is capable of cross-linking, forming a fibrin mesh which 542 is not susceptible to degradation by the HAase. The fibrin/ 543 fibrinogen interact specifically with HA for the formation of 544 ECM either during wound healing or in normal tissues.³² This 545 result is in line with previous studies in which HA hydrogels 546 incorporating fibrin were proposed for cartilage repair 26 given 547 their improved biomechanical properties and the ability to 548 provide an adequate environment for cell encapsulation.

The total PL-proteins release kinetics from the HA hydrogels 550 herein developed was characterized by an initial "burst", 551 followed by a sustained release over time. The release profile 552 observed can be explained by two different processes: (1) the 553 fast elution of large amount of the soluble proteins that are not 554 physically interacting with the HA mesh, facilitated by the 555 strong initial swelling of roughly two times the hydrogel initial 556 weight; (2) a slow release of the proteins entrapped in the 557 hydrogel mesh or adherent to the mesh, that are released by the 558

559 physical degradation of the hydrogel. Since the PL proteins 560 have different isoeletric points (pI), the electrostatic 561 interactions and probability of remaining adsorbed to the HA 562 mesh, which are negatively charged at physiologic pH, will vary. 563 In this way, the albumin, which is the main soluble protein in 564 PL, 33 with an acidic pI (at pH 4.7), is expected to be easily s65 washed out from the HA mesh. On the other hand, most of the 566 GFs present in PL with therapeutic interest have basic pI $567 \text{ (TGF-}\beta \text{ at pH 8.90; PDGF-A at pH 9.52; PDGF-B at pH 9.39;}$ 568 VEGF-1 at pH 8.66; FGF-2 at pH 9.6). So, they are expected to 569 bind electrostatically to the HA matrix and to the insoluble PL 570 proteins to be further released by ion exchange or by the 571 degradation of the HA mesh promoted by HAses released for 572 the ECM remodeling promoted during the wound healing process. In fact, the release of PL-specific GFs from the photo-574 cross-linkable hydrogels, namely FGF-2, was detected only after 575 degradation of the hydrogels in HAase (Figure 4B), whereas no 576 detectable traces of GFs were detected after incubation of the 577 hydrogels in PBS. Studies with FGF-2 have shown that this GF upregulate the migration and proliferation of PDL cells.³⁴ In fact, to fully regenerate functional of periodontal tissues, several GFs and cytokines should interplay in a temporal as spatial controlled manner. 10 Therefore, the controlled release of growth factors is a real asset to our hydrogels.

In line with what has been reported in literature, our findings show that the encapsulation of hPDLFs in nonsupplemented HA hydrogels (PL₀) affects cell proliferation and metabolic 586 activity. The biological performance of cells encapsulated in 587 me-HA hydrogels is affected by the concentration of the macromer, 13,35 as well as by the concentration of photo-589 initiator.³⁵ Furthermore, the exposure to UV radiation was also 590 reported to have adverse effects on viability and cell cycle 591 progression, whereas the differentiation potential remains 592 unchanged.³⁵ Remarkably, the adverse effects of photo-593 encapsulation were overcome by the incorporation of PL into 594 the hydrogels. The viability and metabolic activity of the 595 encapsulated hPDLFs increased proportionally with the 596 incorporation of PL. Previous works have reported the positive 597 effect of PL in the proliferation and maintenance of stemness 598 phenotype of human periodontal ligament stem cells.³⁶ In the 599 same line, we observed, in previous works that (hPDLFs) 600 adhere and proliferate in genipin-cross-linked PL membranes.³ 601 It is known that platelets release several growth factors, namely 602 PDGF and FGF-2, which have a mitogenic effect over human 603 periodontal ligament cells. Moreover, PDGF and FGF-2 604 have been reported to have chemotactic properties over 605 hPDLFs, ^{34,40} while the adhesion sites provided by the clot-606 forming proteins present in PL should facilitated the inward cell 607 migration observed (Figure 6). Therefore, a strategy that can 608 recruit progenitor cells from the preserved periodontal tissue 609 and promote their proliferation and maintenance of stemness 610 to colonize the periodontal defect with cells with great potential 611 to regenerate periodontal tissue would be a valuable asset for 612 periodontal ERT. Hereupon, the first intentional repair 613 promoted by cells originated from periodontal tissues could 614 partially restore the primitive anatomy and function of the 615 periodontium.4

Finally, we have studied the antimicrobial properties of the 617 developed hydrogels, a very important aspect considering the 618 target application. It is known that the main cause of 619 periodontal disease, as well as the main factor of rejection for 620 some of the GTR techniques, is bacterial infections. ^{41,42} The 621 HA was previously described to have bacteriostatic properties

against oral and nonoral bacteria. 43 Carlson et al. 43 suggested 622 that the bacteriostatic effect of HA may be due to the saturation 623 of the bacterial hyaluronate lyase by the excess HA, which 624 prevents the bacteria from maintaining elevated levels of tissue 625 permeability and penetrating the physical defenses of the host. 626 This would enhance the ability of the host's immune system to 627 eradicate pathogens. HA molecules in the hydrogels also form a 628 random network of chains that may act as a sieve preventing 629 the spread of the bacteria. Platelet concentrate (PC) was 630 previously reported to have antimicrobial properties 12 signifi- 631 cantly reducing the growth of methicillin-sensitive or -resistant 632 Staphylococcus aureus, Group A Streptococcus, and Neisseria 633 gonorrhea, among others. As PL is a product of PC activation by 634 freeze/thaw cycles, the same would be expected for this 635 hemoderivative. The obtained results in this study meet with 636 the antimicrobial properties already described in the literature 637 for platelet concentrates. 12 Here, the methicillin resistant 638 Staphylococcus aureus (MRSA) was more susceptible to the 639 hydrogels containing PL₁₀₀ than the other microbial strains 640 tested. Yeaman and Bayer proposed that the bactericidal 641 activity against MRSA involved $\hat{\beta}$ -lysin, which is responsible for 642 blood clotting found after platelets activation. 44,45 β -lysin, 643 which is one of the most abundant compound found in PL after 644 activation 46 has been described to act against bacteria cell-wall, 645 rapidly killing and stopping bacteria reproduction, 44,45 which 646 could explain the results from this study. In addition, other PL- 647 derived molecules with antibacterial properties against Gram+ 648 bacteria could be involved in this response, such as neutrophil 649 activating protein-2 demonstrated capacity to kill Gram-positive 650 and Gram-negative bacteria. 47,48 Although no effect was 651 observed against Gram bacteria and fungus, other factors can 652 be found in PL with bactericidal and fungicidal activity. For 653 instance, Platelet factor-4 can bind to Gram-negative bacteria 654 because it has an affinity for the lipopolysaccharide from these 655 bacteria, facilitating their clearance. 49,50 Nevertheless, further 656 investigation is needed in order to fully understand PL 657 antimicrobial properties against microbial pathogens, especially 658 whether the molecules that demonstrate antimicrobial potential 659 interact alone or together when supplemented as PL and not 660 from induced platelets.

CONCLUSIONS

Overall, our findings demonstrate that is possible to obtain 663 versatile photo-cross-linkable HA-PL hydrogels that provide 664 adequate substrates for hPDLFs attachment and growth while 665 enabling the sustained release of PL and inhibit bacterial 666 growth. Besides providing adequate space and stability, as well 667 as biochemical cues for the regeneration of the lost tissues the 668 hydrogels developed in this study present antimicrobial 669 properties, which can contribute for the prophylaxis, preventing 670 recurrent microbiotic colonization of the periodontal wound. 671 These results suggest the great potential of these materials as 672 cell and/or autologous growth factors carriers for endogenous 673 regenerative technology (ERT) envisioning tissue engineering 674 approaches targeting various tissues, namely the periodontal 675 ligament.

AUTHOR INFORMATION

Corresponding Author *E-mail: megomes@dep.uminho.pt.

I

Pedro S. Babo: 0000-0003-4347-599X

662

677

678

679

680

DOI: 10.1021/acsbiomaterials.6b00508 ACS Biomater. Sci. Eng. XXXX, XXX, XXX—XXX

742

743

682 Author Contributions

683 The manuscript was written through contributions of all 684 authors. All authors have given approval to the final version of 685 the manuscript.

686 Funding

687 The research leading to these results has received funding from 688 Fundação para a Ciência e a Tecnologia (FCT) under project 689 BIBS (PTDC/CVT/102972/2008) and project ACROSS 690 (PTDC/BBB-BIO/0827/2012), from the European Union 691 Seventh Framework Programme (FP7/2007–2013) under 692 grant agreement number REGPOT-CT2012–316331-PO-693 LARIS and from the project "Novel smart and biomimetic 694 materials for innovative regenerative medicine approaches" 695 RL1-ABMR-NORTE-01-0124-FEDER-000016 cofinanced by 696 North Portugal Regional Operational Programme (ON.2–O 7 Novo Norte), under the National Strategic Reference Frame-698 work (NSRF), through the European Regional Development 699 Fund (ERDF).

700 Notes

701 The authors declare no competing financial interest.

D2 ACKNOWLEDGMENTS

703 The authors thank Mariana Oliveira for the support in the 704 dynamic mechanical analysis experiments; Dr. Celia Manaia 705 from the Escola Superior de Biotecnologia (Porto, Portugal) for 706 providing the *Pseudomonas sp.* bacteria; and Dr. Alberta 707 Faustino from the Hospital de S. Marcos (Braga, Portugal) 708 for providing the other bacterial strains. P.S.B. and A.F. 709 acknowledge FCT for the PhD grant SFRH/BD/73403/2010 710 and Post-Doc grant SFRH/BPD/100760/2014.

711 **ABBREVIATIONS**

- 712 PL, platelet lysate
- 713 hPDLFs, human periodontal ligament fibroblasts
- 714 GTR, guided tissue regeneration
- 715 HAase, hyaluronidase
- ERT, endogenous regenerative technology
- 717 MRSA, methicillin -resistant Staphylococcus aureus
- VRSA, vancomycin-resistant Staphylococcus aureus
- 719 HA, hyaluronic acid
- me-HA, methacrylated hyaluronic acid
- 721 GFs, growth factors
- α -MEM, minimum essential medium Eagle alpha modifica-
- 723 tion
- 724 PDMS, polydimethylsiloxane
- 725 MA, methacrylic anhydride
- 726 dH₂O, distilled water
- 727 FTIR, Fourier transform infrared spectroscopy
- ¹HNMR, proton nuclear magnetic resonance
- 729 Dmet, degree of methacrylation
- 730 PL₀, hydrogel incorporating 0 v/v% PL
- PL_{50} , hydrogel incorporating 50 v/v% PL
- 732 PL₁₀₀, hydrogel incorporating 100 v/v% PL
- 733 HAPL, hyaluronic acid hydrogels incorporating PL
- $m_{\rm wet}$, hydrogel wet mass
- 735 m_{dry}, dry hydrogel mass
- m_i , initial weight
- $m_{\rm f}$, final weight
- 738 ELISA, enzyme-linked immunosorbent assay
- 739 FGF-2, fibroblast growth factor-2
- 740 MH, Muller-Hinton (agar)
- 741 DMA, dynamic mechanical analysis

pI, isoelectric point

REFERENCES

- (1) Chen, F. M.; Jin, Y. Periodontal tissue engineering and 744 regeneration: current approaches and expanding opportunities. *Tissue* 745 Eng., Part B 2010, 16 (2), 219–255.
- (2) Susin, C.; Wikesjö, U. M. E. Regenerative periodontal therapy: 30 747 years of lessons learned and unlearned. *Periodontology 2000* **2013**, 62 748 (1), 232–242.
- (3) Chen, F. M.; Zhang, J.; Zhang, M.; An, Y.; Chen, F.; Wu, Z. F. A 750 review on endogenous regenerative technology in periodontal 751 regenerative medicine. *Biomaterials* **2010**, *31* (31), 7892–927.
- (4) Polimeni, G.; Xiropaidis, A. V.; Wikesjo, U. M. E. Biology and 753 principles of periodontal wound healing/regeneration. *Periodontology* 754 2000 2006, 41 (1), 30–47.
- (5) Crespo-Diaz, R.; Behfar, A.; Butler, G. W.; Padley, D. J.; Sarr, M. 756 G.; Bartunek, J.; Dietz, A. B.; Terzic, A. Platelet lysate consisting of a 757 natural repair proteome supports human mesenchymal stem cell 758 proliferation and chromosomal stability. *Cell transplantation* **2011**, 20 759 (6), 797–811.
- (6) Fekete, N.; Gadelorge, M.; Furst, D.; Maurer, C.; Dausend, J.; 761 Fleury-Cappellesso, S.; Mailander, V.; Lotfi, R.; Ignatius, A.; Sensebe, 762 L.; Bourin, P.; Schrezenmeier, H.; Rojewski, M. T. Platelet lysate from 763 whole blood-derived pooled platelet concentrates and apheresis-764 derived platelet concentrates for the isolation and expansion of human 765 bone marrow mesenchymal stromal cells: production process, content 766 and identification of active components. *Cytotherapy* **2012**, *14* (5), 767 540–54.
- (7) Kurita, J.; Miyamoto, M.; Ishii, Y.; Aoyama, J.; Takagi, G.; Naito, 769 Z.; Tabata, Y.; Ochi, M.; Shimizu, K. Enhanced vascularization by 770 controlled release of platelet-rich plasma impregnated in biodegradable 771 gelatin hydrogel. *Annals of thoracic surgery* **2011**, 92 (3), 837–844. 772
- (8) Matsui, M.; Tabata, Y. Enhanced angiogenesis by multiple release 773 of platelet-rich plasma contents and basic fibroblast growth factor from 774 gelatin hydrogels. *Acta Biomater.* **2012**, *8* (5), 1792–801. 775
- (9) Sipe, J. B.; Zhang, J.; Waits, C.; Skikne, B.; Garimella, R.; 776 Anderson, H. C. Localization of bone morphogenetic proteins 777 (BMPs)-2, -4, and -6 within megakaryocytes and platelets. *Bone* 778 **2004**, 35 (6), 1316–22.
- (10) Chen, F. M.; An, Y.; Zhang, R.; Zhang, M. New insights into 780 and novel applications of release technology for periodontal 781 reconstructive therapies. *J. Controlled Release* **2011**, 149 (2), 92–110. 782
- (11) Marx, R. E. Platelet-rich plasma: evidence to support its use. J. 783 Oral Maxillofac. Surg. 2004, 62 (4), 489–96.
- (12) Adam Hacking, S.; Khademhosseini, A., Cells and Surfaces in 785 Vitro. In *Biomaterials Science*, third ed.; Hoffman, A. S., Schoen, F. J., 786 Lemons, J. E., Eds.; Academic Press: New York, 2013; pp 408–427; 787 DOI: 10.1016/B978-0-08-087780-8.00037-1.
- (13) Burdick, J. A.; Chung, C.; Jia, X.; Randolph, M. A.; Langer, R. 789 Controlled degradation and mechanical behavior of photopolymerized 790 hyaluronic acid networks. *Biomacromolecules* **2005**, *6* (1), 386–91.
- (14) Collins, M. N.; Birkinshaw, C. Hyaluronic acid based scaffolds 792 for tissue engineering–a review. *Carbohydr. Polym.* **2013**, 92 (2), 793 1262–79.
- (15) Dahiya, P.; Kamal, R. Hyaluronic Acid: a boon in periodontal 795 therapy. North American journal of medical sciences 2013, 5 (5), 309–796
- (16) Jentsch, H.; Pomowski, R.; Kundt, G.; Göcke, R. Treatment of 798 gingivitis with hyaluronan. J. Clin. Periodontol. 2003, 30 (2), 159–164. 799
- (17) Sukumar, S.; Drizhal, I. Hyaluronic acid and periodontitis. *Acta* 800 *Medica (Hradec Kralove)* **2007**, *50* (4), 225–228.
- (18) Babo, P.; Santo, V. E.; Duarte, A. C.; Correia, C.; Costa, M.; 802 Mano, J. F.; Reis, R. L.; Gomes, M. E. Platelet lysate membranes as 803 new autologous templates for tissue engineering applications. 804 *Inflammation Regener.* **2014**, 34, 33–44.
- (19) Santo, V. E.; Gomes, M. E.; Mano, J. F.; Reis, R. L. Chitosan- 806 chondroitin sulphate nanoparticles for controlled delivery of platelet 807 lysates in bone regenerative medicine. *J. Tissue Eng. Regener. Med.* 808 **2012**, 6 (Suppl3), s47–s59.

- 810 (20) Smeds, K. A.; Pfister-Serres, A.; Miki, D.; Dastgheib, K.; Inoue, 811 M.; Hatchell, D. L.; Grinstaff, M. W. Photocrosslinkable poly-812 saccharides for in situ hydrogel formation. *J. Biomed. Mater. Res.* 813 **2001**, 55 (2), 254–255.
- 814 (21) Williams, C. G.; Malik, A. N.; Kim, T. K.; Manson, P. N.; 815 Elisseeff, J. H. Variable cytocompatibility of six cell lines with 816 photoinitiators used for polymerizing hydrogels and cell encapsulation. 817 *Biomaterials* **2005**, *26* (11), 1211–8.
- 818 (22) Ohno, S.; Ijuin, C.; Doi, T.; Yoneno, K.; Tanne, K. Expression 819 and activity of hyaluronidase in human periodontal ligament 820 fibroblasts. *J. Periodontol.* **2002**, *73* (11), 1331–7.
- 821 (23) Bauer, A. W.; Kirby, W. M.; Sherris, J. C.; Turck, M. Antibiotic 822 susceptibility testing by a standardized single disk method. *Am. J. Clin.* 823 *Pathol.* **1966**, 45 (4), 493–496.
- 824 (24) Weibrich, G.; Kleis, W. K.; Hafner, G.; Hitzler, W. E. Growth 825 factor levels in platelet-rich plasma and correlations with donor age, 826 sex, and platelet count. *Journal of cranio-maxillo-facial surgery: official* 827 publication of the European Association for Cranio-Maxillo-Facial Surgery 828 **2002**, 30 (2), 97–102.
- 829 (25) Wang, H.-L.; Avila, G. Platelet Rich Plasma: Myth or Reality? 830 Eur. J. Dentistry **2007**, 1 (4), 192–194.
- 831 (26) Rampichova, M.; Filova, E.; Varga, F.; Lytvynets, A.; Prosecka, 832 E.; Kolacna, L.; Motlik, J.; Necas, A.; Vajner, L.; Uhlik, J.; Amler, E. 833 Fibrin/hyaluronic acid composite hydrogels as appropriate scaffolds 834 for in vivo artificial cartilage implantation. *ASAIO J.* **2010**, *56* (6), 835 563–8.
- 836 (27) Dorow, C.; Krstin, N.; Sander, F. G. Determination of the 837 mechanical properties of the periodontal ligament in a uniaxial 838 tensional experiment. *J. Orofacial Orthoped.* **2003**, *64* (2), 100–107.
- 839 (28) Beertsen, W.; McCulloch, C. A.; Sodek, J. The periodontal 840 ligament: a unique, multifunctional connective tissue. *Periodontology* 841 2000 **1997**, *13*, 20–40.
- 842 (29) Houck, J. C.; Pearce, R. H. The mechanism of hyaluronidase 843 action. *Biochim. Biophys. Acta* **1957**, 25, 555–562.
- 844 (30) Park, Y. D.; Tirelli, N.; Hubbell, J. A. Photopolymerized 845 hyaluronic acid-based hydrogels and interpenetrating networks. 846 *Biomaterials* **2003**, *24*, 893–900.
- 847 (31) Kucur, M.; Karadag, B.; Isman, F. K.; Ataev, Y.; Duman, D.; 848 Karadag, N.; Ongen, Z.; Vural, V. A. Plasma hyaluronidase activity as 849 an indicator of atherosclerosis in patients with coronary artery disease. 850 *Bratislavske Lekarske Listy* **2009**, *110* (1), 21–26.
- 851 (32) LeBoeuf, R. D.; Raja, R. H.; Fuller, G. M.; Weigel, P. H. Human 852 fibrinogen specifically binds hyaluronic acid. *J. Biol. Chem.* **1986**, 261 853 (27), 12586–12592.
- 854 (33) Burkhart, J. M.; Vaudel, M.; Gambaryan, S.; Radau, S.; Walter, 855 U.; Martens, L.; Geiger, J.; Sickmann, A.; Zahedi, R. P. The first 856 comprehensive and quantitative analysis of human platelet protein 857 composition allows the comparative analysis of structural and 858 functional pathways. *Blood* **2012**, *120* (15), e73–82.
- 859 (34) Shimabukuro, Y.; Terashima, H.; Takedachi, M.; Maeda, K.; 860 Nakamura, T.; Sawada, K.; Kobashi, M.; Awata, T.; Oohara, H.; 861 Kawahara, T.; Iwayama, T.; Hashikawa, T.; Yanagita, M.; Yamada, S.; 862 Murakami, S. Fibroblast growth factor-2 stimulates directed migration 863 of periodontal ligament cells via PI3K/AKT signaling and CD44/864 hyaluronan interaction. *J. Cell. Physiol.* 2011, 226 (3), 809–21.
- 865 (35) Fedorovich, N. E.; Oudshoorn, M. H.; van Geemen, D.; 866 Hennink, W. E.; Alblas, J.; Dhert, W. J. The effect of photo-867 polymerization on stem cells embedded in hydrogels. *Biomaterials* 868 **2009**, 30 (3), 344–53.
- 869 (36) Wu, R. X.; Yu, Y.; Yin, Y.; Zhang, X. Y.; Gao, L. N.; Chen, F. M. 870 Platelet lysate supports the in vitro expansion of human periodontal 871 ligament stem cells for cytotherapeutic use. *J. Tissue Eng. Regener. Med.* 872 **2016**, DOI: 10.1002/term.2124.
- 873 (37) Babo, P. S.; Klymov, A.; teRiet, J.; Reis, R. L.; Jansen, J. A.; 874 Gomes, M. E.; Walboomers, X. F. A Radially Organized Multi-875 patterned Device as a Diagnostic Tool for the Screening of 876 Topographies in Tissue Engineering Biomaterials. *Tissue Eng., Part C* 877 **2016**, 22 (9), 914–922.

- (38) Mumford, J. H.; Carnes, D. L.; Cochran, D. L.; Oates, T. W. 878 The effects of platelet-derived growth factor-BB on periodontal cells in 879 an in vitro wound model. *J. Periodontol.* **2001**, 72 (3), 331–40.
- (39) An, S.; Huang, X.; Gao, Y.; Ling, J.; Huang, Y.; Xiao, Y. FGF-2 881 induces the proliferation of human periodontal ligament cells and 882 modulates their osteoblastic phenotype by affecting Runx2 expression 883 in the presence and absence of osteogenic inducers. *Int. J. Mol. Med.* 884 **2015**, 36 (3), 705–11.
- (40) Boyan, L. A.; Bhargava, G.; Nishimura, F.; Orman, R.; Price, R.; 886 Terranova, V. P. Mitogenic and chemotactic responses of human 887 periodontal ligament cells to the different isoforms of platelet-derived 888 growth factor. *J. Dent. Res.* **1994**, 73 (10), 1593–600.
- (41) Mandell, R. L.; Socransky, S. S. A selective medium for 890 Actinobacillus actinomycetemcomitans and the incidence of the 891 organism in juvenile periodontitis. *J. Periodontol.* **1981**, 52 (10), 892 593–8.
- (42) Newman, M. G.; Socransky, S. S.; Savitt, E. D.; Propas, D. A.; 894 Crawford, A. Studies of the microbiology of periodontosis. *J.* 895 Periodontol. **1976**, 47 (7), 373–9.
- (43) Carlson, G. A.; Dragoo, J. L.; Samimi, B.; Bruckner, D. A.; 897 Bernard, G. W.; Hedrick, M.; Benhaim, P. Bacteriostatic properties of 898 biomatrices against common orthopaedic pathogens. *Biochem. Biophys.* 899 *Res. Commun.* **2004**, 321 (2), 472–478.
- (44) Pastagia, M.; Schuch, R.; Fischetti, V. A.; Huang, D. B. Lysins: 901 the arrival of pathogen-directed anti-infectives. *J. Med. Microbiol.* **2013**, 902 62 (Pt 10), 1506–1516.
- (45) Schuch, R.; Lee, H. M.; Schneider, B. C.; Sauve, K. L.; Law, C.; 904 Khan, B. K.; Rotolo, J. A.; Horiuchi, Y.; Couto, D. E.; Raz, A.; 905 Fischetti, V. A.; Huang, D. B.; Nowinski, R. C.; Wittekind, M. 906 Combination therapy with lysin CF-301 and antibiotic is superior to 907 antibiotic alone for treating methicillin-resistant Staphylococcus 908 aureus-induced murine bacteremia. *J. Infect. Dis.* **2014**, 209 (9), 909 1469–78.
- (46) Yeaman, M. R.; Bayer, A. S. Antimicrobial peptides from 911 platelets. *Drug Resist. Updates* 1999, 2, 116–126.
- (47) Krijgsveld, J.; Zaat, S. A.; Meeldijk, J.; van Veelen, P. A.; Fang, 913 G.; Poolman, B.; Brandt, E.; Ehlert, J. E.; Kuijpers, A. J.; Engbers, G. 914 H.; Feijen, J.; Dankert, J. Thrombocidins, microbicidal proteins from 915 human blood platelets, are C-terminal deletion products of CXC 916 chemokines. J. Biol. Chem. 2000, 275 (27), 20374–81.
- (48) Lam, F. W.; Vijayan, K. V.; Rumbaut, R. E. Platelets and their 918 interactions with other immune cells. *Comprehensive Physiology* **2015**, 5 919 (3), 1265–1280.
- (49) Krauel, K.; Weber, C.; Brandt, S.; Zahringer, U.; Mamat, U.; 921 Greinacher, A.; Hammerschmidt, S. Platelet factor 4 binding to lipid A 922 of Gram-negative bacteria exposes PF4/heparin-like epitopes. *Blood* 923 **2012**, 120 (16), 3345–52.
- (50) Hamzeh-Cognasse, H.; Damien, P.; Chabert, A.; Pozzetto, B.; 925 Cognasse, F.; Garraud, O. Platelets and infections - complex 926 interactions with bacteria. *Front. Immunol.* **2015**, *6*, 82.